Clinical Validation of the Cervista HPV HR Test According to the International Guidelines for Human Papillomavirus Test Requirements for Cervical Cancer Screening

Aniek Boers, Rong Wang, Lorian Slagter-Menkema, Bettien M. van Hemel, Hilde Ghyssaert, Ate G. J. van der Zee, G. Bea A. Schuurs-Wisman, Ed Schuuring*

*Bijbehorende auteur voor dit werk

Onderzoeksoutput: ArticleAcademicpeer review

18 Citaten (Scopus)
296 Downloads (Pure)

Samenvatting

This study demonstrates that both the clinical sensitivity and specificity of the Cervista HPV HR test for high-risk human papillomavirus (HPV) detection are not inferior to those of the Hybrid Capture 2 (HC2) test. The intra- and interlaboratory reproducibilities of Cervista were 92.0% (kappa, 0.83) and 90.4% (kappa, 0.80), respectively. The Cervista HPV HR test fulfills all the international HPV test requirements for cervical primary screening purposes.

Originele taal-2English
Pagina's (van-tot)4391-4393
Aantal pagina's3
TijdschriftJournal of Clinical Microbiology
Volume52
Nummer van het tijdschrift12
DOI's
StatusPublished - dec-2014

Citeer dit